Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 5/20 | 0.71 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.71 |
| ▸ | DAO | P14920 | 3/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA3 | P07451 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA5A | P35218 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.52 |
| ▸ | KDM5A | P29375 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | PARP1 | P09874 | 2/20 | 0.42 |
| ▸ | F11 | P03951 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3385284 | 1.00 | PDE3B (0.71) | PDE3BPDE3ADAOCA12CA9 | |
| SCHEMBL29902532 | 0.83 | PDE3B (1.00) | PDE3BPDE3ADAOCA12CA9 | |
| SCHEMBL368707 | 0.83 | PDE3B (1.00) | PDE3BPDE3ADAOCA12CA9 | |
| SCHEMBL25903981 | 0.80 | PDE3B (0.61) | PDE3BPDE3ACA12CA9CA1 | |
| SCHEMBL584978 | 0.75 | ALDH1A1 (0.52) | PDE3BPDE3ADAOPARP1HRH4 | |
| SCHEMBL1357945 | 0.74 | PDE3B (0.59) | PDE3BPDE3ACA12CA9CA1 | |
| SCHEMBL35211851 | 0.74 | PDE3B (0.59) | PDE3BPDE3ACA12CA9CA1 | |
| SCHEMBL30300382 | 0.73 | DAO (0.51) | PDE3BPDE3ADAOKDM5APARP1 | |
| SCHEMBL30433593 | 0.73 | PDE3B (0.59) | PDE3BPDE3ACA12CA9CA1 | |
| SCHEMBL17067225 | 0.72 | FGFR1 (0.59) | PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240335432-A1 | THERAPEUTIC COMPOUND FOR NEURONAL CEROID LIPOFUSCINOSIS | JCR PHARMACEUTICALS CO., LTD. (JP) | 2024-10-10 | — | — | US | disclosed |
| WO-2023034553-A1 | THERAPEUTIC COMPOUND FOR NEURONAL CEROID LIPOFUSCINOSIS | JCR PHARMACEUTICALS CO., LTD. (JP) | 2023-03-09 | — | — | WO | disclosed |
| US-20230060797-A1 | THERAPEUTIC COMPOUND FOR NEURONAL CEROID LIPOFUSCINOSIS | JCR PHARMACEUTICALS CO., LTD. (JP) | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230060797-A1 | THERAPEUTIC COMPOUND FOR NEURONAL CEROID LIPOFUSCINOSIS | CLN6, GBA2, GBA1 | PDE3B 824/4885PDE3A 574/4885DAO 835/4885 |
| US-20240335432-A1 | THERAPEUTIC COMPOUND FOR NEURONAL CEROID LIPOFUSCINOSIS | CLN6, GBA2, GBA1 | PDE3B 841/4885PDE3A 580/4885DAO 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.